2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care

New and emerging medical therapies and evidence have changed the landscape for managing people with type 2 diabetes (T2D) with established cardiovascular disease (CVD) and those with cardiovascular risk factors. Previously, guidelines gauged good diabetes care primarily based on glycated haemoglobin (HbA1c) targets [1], but recent updates have represented a major shift, now recommending a multimorbidity risk management approach, mainly based on cardiovascular outcome trials (CVOTs). Effective glycaemic control also remains an important consideration for prevention or improvement of microvascular disease.

Source: Primary Care Diabetes - February 16, 2022 Category: Primary Care Authors: S. Seidu, X. Cos, S. Brunton, S.B. Harris, S.P.O. Jansson, M. Mata-Cases, A.M.J. Neijens, P. Topsever, K. Khunti Source Type: research